바이오인

 

 

Challenges and Opportunities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . v

Chapter 1
Finding New Medicines: The R&D Process . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
    Making Progress Possible: U.S. Biopharmaceutical Companies Lead the World . . . . . 2
    The Uncertain R&D Equation: Many Steps + Many Years = ? . . . . . . . . . . . . . . . . . . . . 3
     R&D Details . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
     Medical Advances: Recent Approvals and Medicines in Development . .  . . . . . . . . . . 6

Chapter 2
Science and Policy: Shaping the Future of Medical Progress . . . . . . . . . . . . . . . . . . . . . 11
    Toward Greater Precision in Research and Care . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
     Incremental Innovation: Cumulative Advances for More Patient Benefit . . . . . . . . . . . . 14
     Policy Issues Can Affect Medical Progress . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16

Chapter 3
The Burden of Disease: New Medicines Help Fight the Epidemic . . . . . . . . . . . . . . . . . . 19
    Chronic Disease in the U.S.: A Growing Problem for Patients and Society .. . . . . . . . . 20
    Chronic Diseases: Costing Lives, Reducing Quality of Life .  . . . . . . . . . . . . . . . . . . . . . . 21
    Chronic Diseases: Often Preventable, Frequently Manageable . . .  . . . . . . . . . . . . . 22
    The Partnership to Fight Chronic Disease: Expanding Access to Prevention and Care . . 24

Chapter 4
Health Care Value: Medicines Help Control Costs and Improve Lives . . . . . . . . . . . . . . . 27
    New Medicines: Improving Life for Patients . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
    New Medicines: Helping Control Health Care Costs . . . . . . . . . . . . . . . . . . . . . . . . . . 30
    Proportion of Health Care Spending on Medicines Remains Small .. . . . . . . . . . . . . . 34

Chapter 5
    Health Care Access: Connecting Patients with Scientific Advances. . . . . . . . . . . . . . . . . 37
    Partnership for Prescription Assistance: Entrée to Progress for Uninsured and
    Low-income Patients . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
    Better Access to Care, Savings, and High Satisfaction for Medicare Beneficiaries
    with Part D . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39

Conclusion
Continued Progress Means Supporting R&D. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43

Appendix . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
    Member Companies . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
    PhRMA Annual Membership Survey Definitions of Terms . . . . . . . . . . . . . . . . . . . . 49
    List of Tables: Detailed Results from the PhRMA Annual Membership Survey . . . . . 51

 

 

 

 

 

 

Creating better treatments for patients is the research-based biopharmaceutical industry’s core mission. Fulfilling this mission involves both successes and setbacks.

 

R&D: America’s biopharmaceutical companies continue to lead the world in investing in the research and development (R&D) of new medicines, and in producing treatment advances. Science today offers more promise for finding better treatments than ever before, thanks to new technologies and new knowledge.

 

Yet, the process carries the substantial risk of failure inherent in all scientific discovery. It also has exceptionally large costs and long timelines due to the complex scientific hallenges of drug development, including the rigorous testing protocols that protect patient safety.

 

Public Policy: The environment for innovation includes public policies, such as patent protections and incentives for discovery. Today, more research and development of new medicines is taking place in the U.S. than in any other country. Public policies that support medical progress are a critical underpinning of the large-scale effort to discover new medicines that will make progress against disease.